{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:20:06Z","timestamp":1792002006208,"version":"4.4.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Although AD and HS are significantly different clinically, they share common systemic comorbidities and some immunological pathways. The aim of this multicentric Italian retrospective study is to assess therapeutic effects of upadacitinib on concomitant HS in AD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Multicentric, observational, real-life retrospective study on 195 patients with moderate to severe AD treated with upadacitinib. Specifically, a subgroup analysis of AD+HS patients was conducted. Demographic, clinical data, outcome measures (EASI, NRS itch, sleep and pain, DLQI POEM and ADCT) were collected at baseline (week 0) and at subsequent time points (week 4, week 16, week 32, and week 52). Additionally, IHS4 IHS4\u201355 and HiSCR were the tools used to evaluate the clinical course of HS in the AD+HS subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 195 AD patients were included, 7 (3,6%) patients also suffered of concomitant HS. In the AD+HS subgroup, mean IHS4 decreased from 6.9 \u00b1 4.3 at baseline to 2.2 \u00b1 1.8 at week 16 and 0.2 \u00b1 0.5 at week 32. Reductions of mean baseline severity of HS tool (IHS4) score was detected as early as after only 4\u00a0weeks of treatment. Accordingly, HiSCR and HIS4-S5 were achieved by 4\/7 patients at week 4, 5\/6 at week 16, and 4\/4 at week 32.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In the AD+HS subgroup, improvements were observed for both AD and HS-specific outcomes. Our data, although preliminary, show that upadacitinib could be a valid therapeutic choice in the treatment of patients with AD and concomitant HS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1770969","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:06:15Z","timestamp":1772003175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Beneficial effects of upadacitinib on a subgroup of patients with atopic dermatitis and hidradenitis suppurativa: a multicenter, real-world retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"F.","family":"Russo","sequence":"first","affiliation":[{"name":"Dermatological Department, Istituto Dermopatico dell\u2019Immacolata, Istituto Dermopatico dell'Immacolata - Istituto Scientifico di Ricerca, Ricovero e Cura (IDI-IRCCS), Dermatological Research Hospital","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Schettini","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Ferrara","place":["Ferrara, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. L.","family":"Scaglione","sequence":"additional","affiliation":[{"name":"Bioinformatics Unit, Istituto Dermopatico dell\u2019Immacolata, Istituto Dermopatico dell'Immacolata - Istituto Scientifico di Ricerca, Ricovero e Cura (IDI-IRCCS), Dermatological Research Hospital","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gori","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]},{"name":"Complex Operating Unit (U.O.C.) Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Manzo Margiotta","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pisa","place":["Pisa, Italy"]},{"name":"Health Science Interdisciplinary Center, Sant\u2019Anna School of Advanced Studies","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Del Duca","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department Of Medical And Cardiovascular Sciences, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bianchelli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Istituto Nazionale di Riposo e Cura per Anziani, Istituto Nazionale di Ricovero e Cura degli Anziani (INRCA)-IRCCS Hospital","place":["Ancona, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]},{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Dermatology Section, Department of Medicine and Surgery, University of Perugia","place":["Perugia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Giuliani","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Polyclinic Hospital \u201cSS Annunziata\u201d, Department of Medicine and Aging Sciences, University \u201cG. D\u2019Annunzio\u201d","place":["Chieti, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Corbeddu","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Galluzzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione Policlinico \u201cTor Vergata\u201d","place":["Rome, Italy"]},{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000907","article-title":"Meeting the needs of patients with atopic dermatitis: A multidisciplinary approach","volume":"33","author":"Russo","year":"2022","journal-title":"Dermatitis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.051","article-title":"Hidradenitis suppurativa and atopic dermatitis: A 2-way association","volume":"85","author":"Sherman","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jdin.2021.04.006","article-title":"Atopic dermatitis is associated with hidradenitis suppurativa diagnosis: A single institution retrospective cohort study","volume":"4","author":"Kaakati","year":"2021","journal-title":"JAAD Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.126","article-title":"Atopic dermatitis and hidradenitis suppurativa: An under-recognized pair","volume":"85","author":"Rick","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","article-title":"Increasing comorbidities suggest that atopic dermatitis is a systemic disorder","volume":"137","author":"Brunner","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2340\/00015555-1898","article-title":"The potential role of impaired Notch signalling in atopic dermatitis","volume":"95","author":"Melnik","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.07.020","article-title":"Expression of innate defense antimicrobial peptides in hidradenitis suppurativa","volume":"66","author":"Hofmann","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000545227","article-title":"Evaluation of upadacitinib efficacy in the treatment of atopic dermatitis of sensitive areas","volume":"241","author":"Gori","year":"2025","journal-title":"Dermatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/medicina59040801","article-title":"Hidradenitis suppurativa and JAK inhibitors: a review of the published literature","volume":"59","author":"Martora","year":"2023","journal-title":"Med (Kaunas)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jdv.18632","article-title":"Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa","volume":"37","author":"Tzellos","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.001","article-title":"Demographic and health care service utilization by 4417 patients with hidradenitis suppurativa","volume":"77","author":"Shalom","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00798-0","article-title":"Long-term effectiveness and safety of upadacitinib for atopic dermatitis in a real-world setting: an interim analysis through 48 weeks of observation","volume":"24","author":"Chiricozzi","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2344591","DOI":"10.1080\/09546634.2024.2344591","article-title":"Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study","volume":"35","author":"Hagino","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/CCID.S329442","article-title":"Practical use of upadacitinib in patients with severe atopic dermatitis in a real-world setting: A systematic review","volume":"17","author":"Ibba","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01352-4","article-title":"Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan","volume":"44","author":"Hagino","year":"2024","journal-title":"Clin Drug Investig"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.12.046","article-title":"Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study","volume":"92","author":"Ackerman","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e002049","DOI":"10.1136\/rmdopen-2021-002049","article-title":"Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.047","article-title":"Real-world safety and clinical response of Janus kinase inhibitor Upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study","volume":"87","author":"Kozera","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jid.2023.07.023","article-title":"Rapid attenuation of B-cell and IFN-\u03b3-associated chemokines in clinical responders to jak inhibition with upadacitinib in hidradenitis suppurativa","volume":"144","author":"Flora","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.06.019","article-title":"A systematic review of promising therapeutic targets in hidradenitis suppurativa: acritical evaluation of mechanistic and clinical relevance","volume":"141","author":"Frew","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.014","article-title":"Selective small molecule inhibitors for hidradenitis suppurativa: Today and tomorrow","volume":"91","author":"Jaguan","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"111435","DOI":"10.1016\/j.intimp.2023.111435","article-title":"A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment","volume":"127","author":"Heidari","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16885","article-title":"Risk of infection in patients with hidradenitis suppurativa on biologics or other immunomodulators: a systematic review and meta-analysis","volume":"63","author":"Lazaridou","year":"2024","journal-title":"Int J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","article-title":"The infectious complications of atopic dermatitis","volume":"126","author":"Wang","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1770969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:06:16Z","timestamp":1772003176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1770969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1770969"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1770969","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1770969"}}